A novel therapeutic strategy for Mycoplasma synoviae infection: Elucidating the synergistic effects and underlying mechanisms of Tilmicosin and Sinomenine Authors: Baoyi Deng, Xueyan Wang, Ming Li, Weihuo Li, Yangshuo Li, Jing Chang, Yu Wang, Zhongjia Yu, Nan Zhang Published: 2026 ABSTRACT AbstractMycoplasma synoviae (MS) is an important poultry pathogen that causes multisystem pathological damage, particularly infectious synovitis, resulting in significant economic losses to the poultry industry. Tilmicosin (TMS) is a first-line antimicrobial for mycoplasma infections; however, its limited penetration into joint tissues of MS-infected chickens compromises clinical efficacy. Sinomenine (SIN), an alkaloid extracted from Stephania tetrandra, exhibits specific anti-arthritic and anti-inflammatory effects. Previous studies have shown that combined administration of TMS and SIN produces synergistic effects against MS infection, although the underlying mechanism remains unclear. This study aimed to elucidate the synergistic mechanism of TMS and SIN by analyzing pharmacokinetic changes and anti-inflammatory actions in MS-infected chickens.Microdialysis was used to compare the pharmacokinetics of TMS and SIN administered alone or in combination. Knee joints were collected for histopathological examination using hematoxylin–eosin and safranin O–fast green staining. Inflammatory cytokine mRNA levels in synovial tissues were quantified by RT-PCR, while the expression and subcellular localization of JAK1, p-JAK1, STAT3 and p-STAT3 were evaluated by Western blotting and four-color immunofluorescence.Combined treatment significantly increased the area under the concentration–time curve of TMS during the first three days, while reducing SIN exposure during the early stage. The bacterial load of MS was significantly reduced in the MIX group compared with monotherapy. SIN markedly alleviated synovial and cartilage damage, downregulated pro-inflammatory cytokines, and inhibited activation of the JAK/STAT signaling pathway. These findings indicate that SIN enhances TMS accumulation at joint sites and exerts synergistic anti-inflammatory effects, providing a scientific basis for optimized clinical treatment of MS infection.Keywords: Mycoplasma Synovial, Tilmicosin, Sinomenine, Combination medication, Inflammatory factors Introduction Mycoplasma synoviae (MS) has emerged as a globally significant epizootic pathogen in poultry production, with prevalence rates underscoring its pandemic potential. In commercial laying hens across Europe, PCR-based detection has revealed infection rates ranging from 29% in Poland to as high as 78.6% in the United Kingdom, with similarly elevated rates reported in Germany (75%), France (68%), and Portugal (66.7%) (Kursa et al., 2019). Serological and molecular surveys in eastern Spain further demonstrated MS seroprevalence of 74% in commercial flocks and 95% in backyard systems, with corresponding PCR positivity rates of 35% and 95%, respectively (Cortés, V. et al., 2021), indicating widespread dissemination across diverse production systems. As a conditional pathogen of considerable epidemiological importance, MS spreads through both horizontal (contact) and vertical (egg-borne) transmission routes (Galluzzo et al., 2022). Infection induces multi-system pathological damage, with typical clinical manifestations including persistent cough and wheezing from respiratory mucociliary dysfunction; claudication and dyskinesia arising from joint synovial bursitis; and reproductive tract infection causing marked reductions in egg production and abnormal eggshell quality (Sun et al., 2017). These pathological processes collectively degrade production performance metrics, including daily weight gain and feed conversion ratio, ultimately increasing flock culling rates and inflicting substantial economic losses on the poultry industry. The rapid inter-flock spread and severe production impacts of MS infection urgently necessitate comprehensive research into transmission mechanisms, vaccine strategies, and biosecurity interventions. Tilmicosin (TMS) is a macrolide antibiotic specifically developed for use in livestock and poultry, and it is widely employed to treat Mycoplasma infections in pigs and chickens. However, with the continued emergence of antimicrobial resistance, clinical isolates of MS exhibiting resistance to TMS have been increasingly reported (Wang et al., 2022). Even with appropriate antimicrobial selection, suboptimal drug concentrations—caused by low dosages or short treatment durations—remain a major factor contributing to the development of resistance. The primary target organs affected by MS infection include the joints, footpads, and keel, where blood circulation is relatively poor. This limited vascularization impedes adequate drug distribution to the sites of infection, thereby reducing therapeutic efficacy and facilitating the emergence of resistance. Yan et al. (2023) reported that although TMS is frequently used to control mycoplasma infections in livestock and poultry, its tissue penetration rate is only 51%. For MS infections, the use of antimicrobial agents alone presents two major challenges. Firstly, the penetration of drugs into joint tissues is limited, which restricts their therapeutic efficacy at the primary sites of infection. Secondly, MS infection is typically chronic in nature—bacteria colonize the joints mainly during the acute phase, while in the later stages, the bacterial load decreases substantially, yet arthritis symptoms often persist (Yan et al., 2023). Consequently, antimicrobial therapy is usually ineffective at this stage, highlighting the need to explore novel therapeutic strategies. In recent years, the combination of natural compounds and antibiotics to achieve reduced toxicity and enhanced efficacy has gained recognition and popularity (Malczak et al., 2023). Sinomenine (SIN) is an alkaloid extracted and isolated from the plant of Tetrandraceae, which has anti-inflammatory and analgesic effects, and has special effects on arthritis (Huang et al., 2022). In the preliminary experiment of this study, an acute infection model of chicken arthritic MS was established, and it was found that TMS combined with SIN showed a synergistic effect on anti-MS infection. After the combination, the number of MS in synovial fluid decreased significantly, and SIN also significantly improved the inflammatory symptoms such as redness, swelling and fever in the affected part. However, the underlying synergistic mechanism remains to be elucidated. TMS can directly kill MS, and SIN may promote the accumulation of TMS in chicken knee joints. In addition, their synergistic effect may also be an effective fit of the dual functions of TMS against MS and SIN against inflammation. Based on this, it is particularly critical to study the dynamic changes of drug concentration in joints and the anti-inflammatory mechanism of SIN on MS-induced arthritis. In this study, microdialysis technology was used to dynamically monitor the drug concentration at the joint site, and the effect of SIN on the joint distribution of TMS was measured by the change of pharmacokinetic parameters. At the same time, molecular biology techniques were used to detect the expression changes of related elements JAK1, p-JAK1, STAT3 and p-STAT3 in IL-6-mediated JAK/STAT signaling pathway, and to preliminarily explore the molecular mechanism of TMS combined with SIN against MS arthritis, in order to provide scientific compatibility basis for clinical treatment of MS infection, and also provide theoretical reference for the combination of other antibacterial drugs and natural drugs. Materials and methods Grouping and challenge methods of experimental animals 8-week-old SPF chickens (Xinxing Dahua Nong Poultry and Egg Co., Ltd.) were randomly divided into 5 groups (n = 6): three experimental groups, one positive control group, and one negative control group. The three experimental groups and the positive control group were challenged with MS standard strain WVU1853T (China Veterinary Drug Supervision Institute) , while the negative control group received a sham treatment. The infection model was established using a dual-route inoculation method, involving subcutaneous injection at the metatarsal pad (0.5 mL per side) combined with intra-articular injection (1 mL per knee joint), administered twice daily at 8-hour intervals for five consecutive days. The inoculum concentration for the experimental and positive control groups was 5 × 10⁸ CFU/mL, whereas the negative control group received an equal volume of sterile PBS.All in vivo experiments were approved by the animal research committees of Foshan University Animal Ethics Committee (Approval number: 2022048). Pharmacokinetics experiment Three groups of infected chickens were administered by gavage with 100 mg/kg b.w. of SIN (Xi'an Ruilin Biotechnology Co., Ltd.) , 15 mg/kg b.w. of TMS (Hubei Ruoming Biotechnology Co., Ltd.) , and a combination of 15 mg/kg b.w. TMS and 100 mg/kg b.w. SIN (once a day for three consecutive days, respectively). The MS-infected chickens were immobilized in the cage, and the knee joint position was fixed by using an MD-2000 linear probe (BioS, USA) to pass through the joint cavity of the chickens, ensuring that the semipermeable membrane part was located in the joint cavity. The joint dialysate at 0 h was collected before drug administration. The joint dialysate was collected every hour during the periods of 1∼12 h, 24∼36 h, and 48∼60 h after drug administration, as well as at 72 h. The dialysate samples were stored in a refrigerator at 4 °C and analyzed by HPLC-MS/MS (LCMS-8045, Shimadzu Corporation, Japan) within two weeks. The microdialysis recovery rate detection method for SIN: The high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was used. The mobile phase consisted of 0.1% formic acid aqueous solution (A) and acetonitrile (B). The ion pairs monitored in the multiple reaction monitoring (MRM) mode were 330.10→181.00 and 330.10→207.00. The limit of detection (LOD) was 2 ng/mL, and the limit of quantification (LOQ) was 5 ng/mL. The linear range was 5–500 ng/mL, with R²>0.999. The in vitro forward recovery rate (RR) and reverse recovery rate (RL) were approximately 39.82% and 40.19%, respectively, at the optimal flow rate of 1.0 μL/min, and they were not significantly correlated with the drug concentration. The in vivo forward recovery rate was approximately 39.92%, and the average reverse recovery rate was 41.68%, which were used to correct the concentration of free SIN in the chicken joint. The microdialysis recovery rate detection method for TMS: The ion pairs monitored in the MRM mode were 869.50→696.40 (quantitative) and 869.50→174.40 (qualitative). The limit of detection was 2 ng/mL, and the limit of quantification was 4 ng/mL. The in vivo average reverse recovery rate was measured to be 41.68% using the reverse dialysis method, indicating stable probe performance in the chicken joint. This recovery rate was used to correct the actual free TMS concentration. Pharmacokinetic parameters such as AUC, Cmax, Tmax, t1/2, and MRT were obtained by fitting with WinNonlin 8.1.0 and subjected to statistical analysis. Pharmacodynamic experiment Chicken knee joint fluid was aseptically collected before the first drug administration and at 24, 48, and 72 h after drug administration, with eight chickens at each time point. The collected joint fluid was diluted 10-fold. A volume of 10 μL of the appropriately diluted fluid was dropped onto an agar plate, which was then incubated in a 5% CO₂ incubator for 7∼10 days. MS counts were performed under a microscope. Clinical symptoms of the infected chickens were compared with those of healthy chickens. At 72 h after the first drug administration, the chickens in each group were euthanized. Their knee joints were dissected out using bone shears and surgical scissors and immersed in a 4% tissue fixative in specimen bottles for more than 48 h. After decalcification, the knee joints were sectioned along the mid-sagittal plane to prepare histological sections. Pathological changes in the synovium were observed by hematoxylin and eosin (HE) staining and safranin O-fast green staining. Detection of mRNA expression of inflammatory factors by RT-PCR Synovial tissues of the knee joints were collected from the healthy group, the infected group, and the treated group (day 3 post-treatment) and immediately snap-frozen in liquid nitrogen for storage. Total RNA was extracted using the RNA extraction kit from Wuhan Seawell Bioengineering Co., Ltd. through the steps of lysis, chloroform separation, isopropanol precipitation, ethanol washing, and dissolution in RNase-free water. Subsequently, 2 μg of RNA was reverse-transcribed into cDNA using the Takara RR036A reverse transcription kit under the conditions of 37°C for 15 min and 85°C for 5 s. A 25 μL reaction mixture containing SYBR Premix Ex Taq II, forward and reverse primers, and cDNA template was prepared and subjected to a two-step PCR program on a Thermo Fisher fluorescence PCR instrument: 95°C for 30 s for initial denaturation, followed by 40 cycles of 95°C for 5 s and 60°C for 30 s. The mRNA levels of NOS, IL-1β, IL-6, IL-17, IFN-γ, TNF-α, and PGE2 were detected, with β-actin as the internal reference gene. The relative expression levels were calculated using the 2^-ΔΔCt method. Western blot combined with immunofluorescence to detect the expression of signaling pathway proteins At the protein level, synovial tissues of knee joint were mechanically ground after EDTA decalcification. The tissues were lysed using the total protein extraction kit from Shanghai Bibo Bioengineering Co., Ltd., and the supernatant was collected by centrifugation at 12,000 × g. The protein concentration was normalized using the BCA method. A volume of 10 μg of the sample was mixed with Loading Buffer and denatured at 90°C for 10 min. Then, the mixture was subjected to 8% SDS-PAGE (70 V→100 V) and transferred to a PVDF membrane activated with methanol in a wet transfer system (constant current 100 mA, 120 min on ice). The membrane was blocked with a protein-free blocking solution at room temperature for 10 min and then incubated with rabbit anti-JAK1, p-JAK1, STAT3, and p-STAT3 (1:1000) from MyBioSource at 4°C overnight. After washing the membrane with TBST for 3 × 10 min, the membrane was incubated with chicken anti-rabbit IgG-HRP (1:5000) at room temperature in the dark for 90 min. Signals were captured using an ECL chemiluminescence imaging system. The relative expression levels of JAK1, p-JAK1, STAT3, and p-STAT3 were calculated using Image J software with β-actin as the internal reference to verify the inhibitory effect of the combined drug treatment on the JAK/STAT pathway. The quadruple immunofluorescence staining technique with paraffin sections was used to assess the subcellular localization and fluorescence intensity of polyclonal-JAK1, polyclonal-STAT3, Phospho-STAT3 (Tyr705), and Phospho-JAK1 proteins in the cartilage tissues of chicken knee joints. The tissues were dehydrated through a gradient of alcohol, cleared with TO type clearing agent, and embedded in paraffin at 58–60 °C. The blocks were then trimmed. Subsequently, the tissues were cut into 3 µm sections using a Leica rotary microtome. The sections were floated out in a water bath at 42 °C, baked at 60 °C for 1 h, and kept at 37 °C overnight. The sections were dewaxed in TO type clearing agent I and II for 15 min each, and then rehydrated through 100%, 95%, 90%, 85%, and 75% ethanol for 2 min each. After washing with PBS, antigen retrieval was performed in pH 9.0 EDTA repair solution in a microwave for 10 min. The sections were then washed on a shaker with PBS for 3 × 5 min after natural cooling. Each section was circled with an immunohistochemistry pen, and 3% H₂O₂ was added to block endogenous peroxidase at room temperature in the dark for 25 min. The sections were washed again with PBS and then blocked with 10% rabbit serum or 3% BSA for 30 min. The primary antibodies (Rabbit JAK1 1:3000, Rabbit STAT3 1:300, Phospho-STAT3 1:2000, Phospho-JAK1 1:3000, all purchased from MyBiosource or Affbiotech) were added in sequence at the appropriate dilutions and incubated at 4 °C in a humidified chamber overnight. The next day, the sections were washed with PBS for 3 × 5 min, and the corresponding HRP-labeled secondary antibodies were added and incubated at room temperature for 50 min. After washing with PBS, the sections were incubated with TSA fluorescence amplification reagent in the dark for 10 min and then washed thoroughly with TBST. After the first round of labeling was completed, the bound antibodies were removed by boiling in pH 6.0 citrate repair solution in a microwave for 10 min. The sections were then blocked with serum again and the remaining three primary antibodies, secondary antibodies, and TSA were incubated in sequence. After quadruple labeling, the nuclei were stained with DAPI for 10 min and washed with PBS. The sections were treated with an autofluorescence quencher for 5 min, rinsed with running water for 10 min, and finally sealed with an anti-fade mounting medium. An inverted fluorescence microscope (Mingmei MF53, MS60 imaging system) was used to collect 2 × images at the corresponding excitation/emission wavelengths, and the expression intensity of each protein in the cell membrane region was evaluated by gray value. Statistical analysis All data are presented as mean ± standard deviation (SD). Pharmacokinetic parameters, including AUC, Cmax, Tmax, t1/2, and MRT, were calculated using Phoenix WinNonlin. Statistical analyses were performed using GraphPad Prism.Differences between two groups were analyzed using Student’s t-test, while comparisons among multiple groups were performed using one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison test. Relative mRNA expression levels were calculated using the 2^-ΔΔCt method with β-actin as the internal reference gene. Protein expression levels obtained from Western blotting and immunofluorescence staining were quantified by gray value analysis using ImageJ.A value of P < 0.05 was considered statistically significant, and P < 0.01 was considered extremely significant. Result Pharmacokinetic characteristics of SIN, TMS, and their combination after administration The free concentrations of SIN and TMS in the joint cavity were dynamically monitored from 0 to 72 h after administration. The concentration–time curves of SIN administered alone or in combination with TMS, as well as those of TMS administered alone or in combination with SIN, are presented in Fig. 1, Fig. 2, respectively. Detailed pharmacokinetic data are provided in Tables 1.1–1.4 in the Appendix. The concentration-time curves of sinomenine concentration in infected-chickens joint from alone and combination administration. The concentration-time curves of tilmicosin concentration in infected-chickens joint from alone and combination administration. The differences in the major pharmacokinetic parameters of SIN, including AUC, Cmax, Tmax, t1/2, and MRT, between monotherapy and combination therapy are shown in Fig. 3, Fig. 4, Fig. 5, Fig. 6, Fig. 7, with detailed values listed in Tables 2.1–2.2 in the Appendix. Compared with the SIN-alone group, combined administration significantly decreased the AUC, Cmax, t1/2, and MRT of SIN on days 1 and 2 (P < 0.05 or P < 0.01), whereas no significant differences were observed on day 3. No significant differences in Tmax were detected throughout the experimental period. Results of the AUC differential analysis. Results of the Cmax differential analysis. Results of the Tmax differential analysis. Results of the t1/2 differential analysis. Results of the MRT differential analysis. The differences in the major pharmacokinetic parameters of TMS between monotherapy and combination therapy are shown in Fig. 8, Fig. 9, Fig. 10, Fig. 11, Fig. 12, and the detailed data are provided in Tables 2.3–2.4 in the Appendix. Compared with TMS alone, combination treatment significantly increased the AUC of TMS on days 1 and 2 (P < 0.05) and extremely significantly increased it on day 3 (P < 0.01). The Cmax of TMS was significantly increased on days 1–3 (P < 0.05). No significant differences in Tmax were observed among the groups. In addition, t1/2 and MRT were significantly increased on day 2 after combined administration (P < 0.05), whereas no significant differences were found on days 1 and 3. Results of the AUC differential analysis. Results of the Cmax differential analysis. Results of the Tmax differential analysis. Results of the t1/2 differential analysis. Results of the MRT differential analysis. Pharmacodynamic Study of SIN and TMS in the Joint of Infected Chickens (1) Changes in bacterial load (1) Changes in bacterial load The bacterial load of MS in the joint of infected chickens after administration of TMS, SIN alone and in combination is shown in Fig. 13, and the analysis of differences in MS quantity is shown in Fig. 14. The results indicate that compared with the control group, administration of SIN alone did not significantly reduce the number of MS. After administration of TMS alone, the number of MS significantly decreased at 48–72 h (P < 0.05). After combined administration of TMS and SIN, the number of MS extremely significantly decreased at 24–72 h (P < 0.01). Moreover, the reduction in MS in the combination group was more significant than that in the TMS-alone group (P < 0.05). (2) Clinical Symptoms and Histopathological Observations (2) Clinical Symptoms and Histopathological Observations Curve of change in the number of MS at the joints after administration of tilmicosin, sinomenine alone and in combination. Differential analysis of change in the number of MS at the joints after administration of tilmicosin, sinomenine alone and in combination. The comparison of joints and foot pads between healthy chickens and MS-infected chickens is shown in Fig. 15. The joints and foot pads of MS-infected chickens were significantly more swollen than those of healthy chickens, and the swollen areas had a sense of heat and fluctuation. Joints and foot pads of control (left) and MS-infected group (right) of Mix group. Safranin O-fast green staining was used to evaluate histopathological changes: The cartilage tissue structure of the healthy group was intact, with clear and distinct layers, and the cartilage layer contained sufficient proteoglycans, with no obvious damage observed (Fig. 16-A). In the MS-infected group, the cartilage layer was disordered, with an incomplete structure and loss of proteoglycans in the cartilage layer (Fig. 16-B). In the groups treated with SIN and TMS alone, the cartilage layer structure was disordered, and the content of proteoglycans in the cartilage layer was reduced (Fig. 16-C,D). In the MIX group, the cartilage tissue was more intact and contained more proteoglycans compared with the two single-treatment groups (Fig. 16-E). The analysis of differences in Safranin O-fast green staining scores is shown in Fig. 17. (A) Cartilage of Control group; (B) Cartilage of MS-infected group; (C) Cartilage of SIN group; (D) Cartilage of TMS group; (E) Cartilage of MIX group. Differential analysis of OARSI. (**:p<0.05, significant difference, ****:p<0.01, extremely significant difference) Histopathological changes were assessed by hematoxylin and eosin (HE) staining: In the healthy group, the surface cartilage layer structure was intact with distinct layers. A thin layer of synovial cells was attached to the surface, and the cell morphology was normal, with no hyperplasia or infiltration of lymphocytes and monocytes (Fig. 18-A). In the MS-infected group, the surface cartilage tissue distribution was disordered. Chondrocytes showed reduced vacuoles and irregular fissures, with an unclear underlying line. The cell morphology changed significantly, and there was massive infiltration of lymphocytes and monocytes around the blood vessels (Fig. 18-B). In the SIN-treated group, the surface cartilage layer structure was damaged, with disordered distribution of chondrocytes and vacuolar degeneration forming irregular fissures (Fig. 18-C). In the TMS-treated group, the surface cartilage layer structure was slightly damaged, with local fibrosis and vacuolar chondrocytes. The degree of inflammatory cell infiltration was significantly reduced (Fig. 18-D). In the MIX group, compared with the two single-treatment groups, the surface cartilage layer structure was more intact, with only a small amount of capillary proliferation. The infiltration of lymphocytes and monocytes was more similar to that of the healthy group (Fig. 18-E). The analysis of differences in HE staining scores is shown in Fig. 19. (A) Control group; (B) MS-infected group; (C) SIN group; (D) TMS group; (E) Mix group. Differential analysis of Pelletier. (**:p<0.05, significant difference, ****:p<0.01, extremely significant difference) Detection of inflammatory Cytokine mRNA expression by RT-PCR The CT values of the reference gene (β-actin) and the inflammatory cytokine genes were detected by RT-PCR, and the relative expression levels were calculated using the 2-ΔΔCt method (Table 1). The differences are shown in Fig. 20. The results show that SIN alone significantly reduced the expression of IL-1β, IL-6, IL-17, NOS, and TNF-α (all P < 0.05); TMS alone only reduced the expression of IL-6 and TNF-α (P < 0.05); the MIX group significantly reduced the expression of NOS, IL-6, IL-17, and PGE2 (P < 0.05). Table 1Relative expression levels of each gene versus the internal reference.Table 1 dummy alt text2-ΔΔctNOSIL-1βIL-6IL-17TNF-αIFN-γPGE2MS-infected5.956911.85047.714916.03633.091611.29783.2759SIN2.85184.22794.289112.14462.250411.00732.4729TMS2.84083.90814.382914.31772.27510.64132.4509MIX2.54425.16674.490411.23242.296711.35372.1720 Relative expression levels of each gene versus the internal reference. Differential analysis of inflammatory factors. (**:p<0.05, significant difference, ****:p<0.01, extremely significant difference) Detection of JAK1, p-JAK1, STAT3, and p-STAT3 protein expression by western blot The protein bands of JAK1, p-JAK1, STAT3, and p-STAT3 were compared with the reference band of β-actin to calculate the grayscale ratio, as shown in Table 2. Compared with the healthy group, the expression levels of JAK1, p-JAK1, STAT3, and p-STAT3 proteins were increased in the infection group. Meanwhile, compared with the infection group, the expression levels of the four proteins were downregulated in all treatment groups, and the downregulation was more significant in the MIX group than in the groups treated with the drugs alone. Table 2Gray-scale ratio of JAK1,p-JAK1,STAT3,p-STAT3/ β -actin.Table 2 dummy alt textGray-scale ratioControlMIXMS-infectedSINTMSJAK1/β-actin0.12080.18150.87530.33510.1860p-JAK1/β-actin0.77260.78491.21250.79820.9915STAT3/β-actin0.10490.23720.34550.28150.3237p-STAT3/β-actin0.24730.29540.67830.54990.6697 Gray-scale ratio of JAK1,p-JAK1,STAT3,p-STAT3/ β -actin. Subcellular localization and activation of JAK1/STAT3 signaling pathway in chicken knee joint tissue assessed by immunofluorescence quadruple staining The results of the subcellular localization and fluorescence intensity of polyclonal-JAK1, polyclonal-STAT3, Phospho-STAT3 (Tyr705), and Phospho-JAK1 proteins in chicken knee joint tissue detected by immunofluorescence quadruple staining are shown in Fig. 21. The P-JAK1 protein is mainly expressed in the cell membrane of bone tissue, with the protein expression intensity being: TMS group, SIN group, MS group > MIX group > Control group. The P-STAT3 protein is mainly expressed in the cell membrane of bone tissue, with the protein expression intensity being: MS group, TMS group, SIN group > MIX group > Control group. The JAK1 protein is mainly expressed in the cell membrane of bone tissue, with the protein expression intensity being: MS group > SIN group > Control group, TMS group, MIX group. The STAT3 protein is mainly expressed in the cell membrane of bone tissue, with the protein expression intensity being: MS group, TMS group, SIN group > MIX group > Control group. Protein expression and fluorescence intensity of polyclonal-JAK1, polyclonal-STAT3, Phospho-STAT3 (Tyr705), Phospho-JAK1 (MS group, TMS group, SIN group, MIX group, Control group) 2X. Discussion In this study, co-administration of SIN and TMS markedly ameliorated joint pathology in MS-infected chickens, as demonstrated by reduced cartilage damage and decreased inflammatory cell infiltration. Notably, the combined treatment exhibited superior efficacy compared with either monotherapy, indicating a synergistic therapeutic effect. This observation is consistent with previous reports that combining natural compounds with antibiotics can enhance therapeutic outcomes while potentially mitigating adverse effects and antimicrobial resistance (Li et al., 2022; Liu et al., 2017; Xiang et al., 2023). From a pharmacokinetic perspective, our findings revealed that co-administration altered the tissue distribution of both agents, characterized by decreased SIN and increased TMS concentrations in joint tissues. This phenomenon is likely attributable to drug–drug interactions involving cytochrome P450 (CYP450) enzymes. SIN is primarily metabolized by CYP3A4 and CYP2C19, whereas macrolide antibiotics such as TMS are known inhibitors of CYP3A4 (Liu et al., 2025; Pérez-Del Palacio et al., 2017; Yao et al., 2007; Zhang et al., 2022). Therefore, TMS may interfere with SIN metabolism, thereby modifying its bioavailability and tissue distribution. Similar interactions between TCM-derived compounds and conventional drugs have been reported, supporting the rationale for combination therapy while also highlighting the need for careful pharmacokinetic evaluation. At the molecular level, MS infection significantly activated the JAK/STAT signaling pathway, leading to enhanced phosphorylation of JAK1 and STAT3 and subsequent upregulation of downstream inflammatory mediators. SIN treatment effectively suppressed this pathway, suggesting that its anti-inflammatory activity is closely associated with inhibition of JAK/STAT signaling. In contrast, TMS primarily reduced the expression of upstream cytokines such as IL-6 and TNF-α, indicating a distinct but complementary mechanism of action. Importantly, the combined treatment exerted a dual regulatory effect by both attenuating cytokine production and blocking intracellular signal transduction, thereby producing a more pronounced anti-inflammatory response. In addition to JAK/STAT signaling, NF-κB is a well-established regulator of inflammatory gene expression and macrophage activation (Hayden et al., 2011). Although NF-κB activity was not directly assessed in this study, the observed reduction in pro-inflammatory cytokines suggests that this pathway may also be involved. Future studies are warranted to further elucidate the interplay between NF-κB signaling and macrophage polarization in the context of SIN and TMS co-treatment. Despite these promising findings, several limitations should be acknowledged. First, macrophage polarization was not directly assessed, and the inclusion of phenotypic markers such as CD86 (M1) and CD206 (M2) would strengthen the mechanistic interpretation. Second, the study primarily focused on the JAK/STAT pathway, while other key inflammatory pathways, including NF-κB and the NLRP3 inflammasome, were not comprehensively investigated. Third, although pharmacokinetic interactions were proposed, direct experimental validation at the enzymatic level is still lacking. Finally, as this study was conducted in an animal model, further clinical validation is required to confirm its translational relevance. Nevertheless, this study possesses several notable strengths. It integrates pharmacokinetic analysis, histopathological evaluation, and molecular investigations to provide a comprehensive understanding of the synergistic effects of SIN and TMS. Moreover, it offers novel insights into the combined use of natural compounds and antibiotics as a promising therapeutic strategy for MS-induced arthritis. Conclusion The pharmacokinetic results indicated that after combined administration, the distribution of SIN in the joint area decreased, while that of TMS increased. The pharmacodynamic results showed that the reduction in MS bacterial load in the combined treatment group was significantly higher than that in the single treatment groups. MS infection caused significant pathological damage to the chicken joints, and the therapeutic effect in the MIX group was significantly improved compared to the single treatment groups. The mRNA expression levels of IL-1β, IL-6, IL-17, NOS, and TNF-α in the chicken joint tissues were significantly reduced in the SIN group. Western blot analysis revealed that MS infection triggered inflammatory responses by activating the JAK/STAT signaling pathway. SIN inhibited the activation of the JAK/STAT signaling pathway, resulting in downregulation of the expression of inflammatory factors. This study offers novel insights for clinical management of MS infection and provides a reference for rational combination therapy of infectious diseases. Declarations Funding This study is supported financially by National Natural Science Foundation of China (No. 32202866). Availability of data and materials The data supporting this systematic review are from previously reported studies and datasets and have been cited. Ethics approval and consent to participate All in vivo experiments were approved by the animal research committees of Foshan University Animal Ethics Committee (Approval number: 2022048). Consent for publication Not applicable Author contribution Baoyi Deng: Conceptualization, Investigation, Formal analysis, Interpretation of data, Writing – original draft. Xueyan Wang: Conceptualization, Investigation, Formal analysis, Interpretation of data, Writing – original draft. Ming Li, Jing Chang, and Yu Wang: Investigation, Formal analysis, Interpretation of data. Nan Zhang: Conceptualization, Study design, Supervision, Interpretation of data, Funding acquisition. Disclosures The authors declare no conflict of interest. Acknowledgements Not applicable Footnotes Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.psj.2026.107122. Supplementary materials References Associated Data Supplementary Materials Data Availability Statement The data supporting this systematic review are from previously reported studies and datasets and have been cited.